Key Issues in Depression: Highlights From APA 2016

Slides:

Advertisements

Similar presentations

Other Mental Health Issues that Impact Learning

Advertisements

Effectiveness & Cost-Effectiveness of Collaborative Care Depression Treatment in Veterans who screen positive for PTSD Domin Chan, MHS, PhC Northwest HSRD.

Clinical Management of Treatment Resistant Depression

Overall Goals of the STEP-BD Randomized Clinical Trials Pathway Answer the question “What to do next?” when acute depression doesn’t respond to monotherapy.

IzBen C. Williams, MD, MPH Instructor. Lecture - 11 MOOD DISORDERS.

2007. Statistics  2-4 new cases per 100,000/year  1 in 200 people will have an episode of hypomania  Peak age of onset yrs  May have had a previous.

Chapter 2 The Problem of Dual Diagnosis. Dual Diagnosis and Comorbidity Dual diagnosis – Describes individuals who meet diagnostic criteria for a mental.

Psychopharmacology – A brief introduction. Objectives Review general categories of psychiatric disorders Review general categories of psychiatric disorders.

IzBen C. Williams, MD, MPH Instructor. Lecture - 8 MOOD DISORDERS.

Update in the Treatment of Depressive Disorders Renee Lamm MD ABPN, ABAM FAPA, FAAFP.

Update in the Treatment of Depressive Disorders Renee Lamm MD ABPN, ABAM FAPA, FAAFP.

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 25: Bipolar Disorders: Management of Mood Lability.

Mental Health Services, University of Copenhagen 1.

Chapter 18 Bipolar Mood Disorder. Definition 1.Bipolar I disorder # disorder in which at least one manic or mixed episode has occurred # commonly accompanied.

Chapter Depression Barbour, Hoffman, and Blumenthal C H A P T E R.

A2 Skills. Today’s Session You will be assessing yourselves on key skills needed in Psychology. You will be developing your skills of APPLICATION Context.

Bipolar II Disorder. Involves – Major Depressive Episodes and – Hypomanic Episodes Bipolar IIvsBipolar I (Hypomanic + MDD) (Manic + MDD)

Immediate solutions to address demand and capacity pressures in Hospital Eye Services David Geddes Head of Primary Care Commissioning.

Number Needed To Treat (NNT)

Symptom Control and Enhancing Functioning in Schizophrenia

A systematic review of the relationship between substance abuse and psychotropic medication adherence: opportunities to improve outcomes for patients with.

Major Depressive Disorder: Latest Clinical Update

How the Latest Data in MDD Can Guide Treatment Decisions:

Program Overview. Primary Care Approaches to Cognitive Dysfunction in Major Depressive Disorder.

Primary Care Challenges in Depression - To Treat or Refer?

Michael Panzer, MD ThedaCare Behavioral Health

Major Depressive Disorder: Getting the Patient Back to Work

NOACs for Cancer-Associated Thrombosis:

Focus on MDD: Real World Perspectives for Improving Care

Bipolar Disorder in DSM-5 Highlights of changes from DSM-IV-TR to DSM-5 Flavio Guzmán, MD.

Bipolar I Depression Today: The Evolving Understanding of Bipolar Depression Neurobiology and the Relation to Diagnosis.

Bipolar Disorder: Latest Clinical Update

What Is Major Depressive Disorder (MDD)?

Best Practices in Huntington Disease

The Patient Journey to Remission in MDD: A Collaborative Approach

From the 2015 Conferences to the Clinic

From Conference to the Clinic

The Comprehensive Major Depressive Disorder Care Team

Optimizing Quality of Life and Mental Health in Patients With Psoriasis.

The Mood Disorder Spectrum

What Would You Do in This Case of MDD?

When Patients With Depression Have Cognitive Deficits

Diabetes and Psychiatric Disorders: Can they Co-exist?

Screening and Diagnosing Postpartum Depression

Managing Depression in Bipolar I Disorder

Managing Depression is a Team Effort:

Tackling Atopic Dermatitis

Expert Debate in MDD.

Pseudobulbar Affect or Psychiatric Condition?

Lurasidone Flavio Guzmán, MD.

What Is Bipolar Disorder?

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Program Overview. Major Depressive Disorder: The Challenging Patient and the Goal of Recovery.

Program Goals Overview Is NEDA a Reasonable Target?

Substance Use Disorder

After the Baby Comes.

Scientific Update.

Clinical Pearls on Hot Topics in MS

New Approaches to Insomnia Management: Impact on Clinical Practice

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

The Challenges of Bipolar Disorders

New Trends in Treatment for Major Depressive Disorder

Communicating With Your Patients About Major Depressive Disorder

The ABCs of Pharmacogenomics in Clinical Practice

What You Need To Know To Effectively Manage Patients With MDD Key Terms (cont)

Program Goals Overview Is NEDA a Reasonable Target?

MS, Age, and Immune Function

Widening the Options for Major Depressive Disorder

Understanding the Role of Disability in MS Management

A Fresh Perspective on Hypoactive Sexual Desire Disorder

Presentation transcript:

Key Issues in Depression: Highlights From APA 2016

New Research on Suicidality, Treatment Resistant Depression, and Cognitive Impairment

A Prospective Study of Antidepressant Adherence and Suicide Risk

A Prospective Study of Antidepressant Adherence and Suicide Risk: Results

Treatment Resistant Depression (TRD) Diagnostic Profile and Therapeutic Role of Antipsychotics And Mood Stabilizers

Treatment Resistant Depression Results

Impact of Vortioxetine on Functional Capacity in MDD Patients With Cognitive Dysfunction: A UCSD Performance-based Skills Assessment Post-hoc Analysis

Functional Capacity Results

New Research on Brexpiprazole, Levomilnacipran, and Cognition

Residual Patient-Reported Cognitive Dysfunction: A Potential Predictor for Relapse in MDD?

Residual Patient-Reported Cognitive Dysfunction: A Potential Predictor for Relapse in MDD? (cont)

Effect of Adjunctive Brexpiprazole on Cognitive and Physical Functioning in Five Exploratory, Open-Label Studies on Major Depressive Disorder

Effect of Adjunctive Brexpiprazole Results

Direct and Indirect Effects of Levomilnacipran ER on Functional Impairments in MDD Patients With Cognitive Difficulties: Post-Hoc Path Analyses

Direct and Indirect Effects of Levomilnacipran ER Results

The Effect of Vortioxetine on Cognitive Dysfunction

Efficacy of Vortioxetine on Cognitive Function in Working Subjects With Major Depressive Disorder (Post-hoc Analysis)

Efficacy of Vortioxetine on Cognitive Function Results

Research on Depression With Mixed Features

Baseline Differences in Two Depressed Populations: Major Depression With Mixed Features Vs Bipolar I Depression

Baseline Differences in Two Depressed Populations (cont)

Baseline Differences in Two Depressed Populations (cont)

Clinical Characteristics, Comorbidities and Health Care Utilization Among Patients With Major Depressive Disorder With Mixed Features

Patients With Major Depressive Disorder With Mixed Features (cont)

Lurasidone for Major Depressive Disorder With Mixed Features: Effect of Irritability, Post Hoc Analysis

Lurasidone for Major Depressive Disorder With Mixed Features: Effect of Irritability, Post Hoc Analysis Results

Abbreviations

Abbreviations (cont)

Abbreviations (cont)